本文關(guān)鍵詞： 乳腺癌 SF CA125 CA153 診斷　出處：《河北醫(yī)科大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:利用化學(xué)發(fā)光免疫分析法對(duì)乳腺癌患者血清SF(Serum ferritin,血清鐵蛋白)、CA125(Carbohydrate antigen 125,糖類抗原125)和CA153(Carbohydrate antigen 153,糖類抗原153)進(jìn)行檢測(cè),探討其在乳腺癌診斷中的臨床應(yīng)用價(jià)值。材料與方法:1樣本收集2013年12月至2014年12月邢臺(tái)市人民醫(yī)院腫瘤內(nèi)科和腫瘤外科收治的乳腺癌患者156例,其中乳腺癌患者92例,乳腺良性疾病患者64例,所有乳腺癌癌患者均經(jīng)組織病理學(xué)或細(xì)胞學(xué)確診。另選擇40例門診健康體檢者作為健康對(duì)照。對(duì)所有觀察對(duì)象進(jìn)行血清腫瘤標(biāo)志物SF、CA125、CA153測(cè)定。2腫瘤標(biāo)志物的測(cè)定SF、CA125和CA153均采用化學(xué)發(fā)光法測(cè)定。3數(shù)據(jù)的統(tǒng)計(jì)學(xué)分析采用SPSS17.0軟件對(duì)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)分析,數(shù)據(jù)資料呈正態(tài)分布,以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,組間比較采用t檢驗(yàn);定性資料組間的比較采用x2檢驗(yàn)。檢驗(yàn)水準(zhǔn)α=0.05。結(jié)果:1血清SF、CA125和CA153在乳腺癌組、乳腺良性疾病組和健康體檢組表達(dá)水平比較血清SF表達(dá)水平,乳腺癌組乳腺良性疾病組健康體檢組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。血清CA125和CA153表達(dá)水平,乳腺癌組顯著高于乳腺良性疾病組和健康體檢組,差異有統(tǒng)計(jì)學(xué)意義(P0.05);乳腺良性疾病組和健康體檢組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。2血清SF、CA125和CA153在不同分期乳腺癌表達(dá)水平比較血清SF表達(dá)水平:III期II期I期,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。血清CA125、CA153表達(dá)水平:I期低于II期和III期,差異有統(tǒng)計(jì)學(xué)意義(P0.05);II期和III期比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。三項(xiàng)腫瘤標(biāo)志物血清表達(dá)水平均與乳腺癌分期呈正相關(guān)。3血清SF、CA125和CA153診斷價(jià)值評(píng)估(以乳腺良性疾病組作為對(duì)照)診斷乳腺癌的靈敏度:SFCA153CA125;特異度:CA153CA125SF。通過約登指數(shù)評(píng)估這三項(xiàng)腫瘤標(biāo)志物的診斷價(jià)值,CA153最高,為0.5074;CA125最低,為0.2867。三項(xiàng)聯(lián)合檢查診斷乳腺癌的靈敏度達(dá)78.26%。結(jié)論:1 SF,CA125和CA153在乳腺癌的診斷中均有很好的應(yīng)用價(jià)值,可作為乳腺癌的鑒定指標(biāo)。2 SF,CA125和CA153均與乳腺癌分期呈正相關(guān),血清水平越高提示著患者的病情越嚴(yán)重。3 SF診斷乳腺癌的靈敏度最高,CA153的特異性最好。綜合評(píng)估,CA153診斷乳腺癌的價(jià)值最高,SF次之,CA125最差。三項(xiàng)聯(lián)合檢測(cè)能提高診斷乳腺癌的靈敏度。
[Abstract]:Objective: to detect serum SF(Serum ferritin, serum ferritin, carbohydrate antigen 125, carbohydrate antigen 125 and CA153(Carbohydrate antigen 153, carbohydrate antigen 153 in patients with breast cancer by chemiluminescence immunoassay. Materials and methods: from December 2013 to December 2014, 156 cases of breast cancer were collected from Department of Oncology and Cancer surgery, Xingtai people's Hospital, including 92 cases of breast cancer. 64 patients with benign breast disease, All patients with breast cancer were confirmed by histopathology or cytology. Another 40 outpatient healthy persons were selected as healthy controls. The serum tumor marker SFCA125CA153 was used to determine the tumor marker SFCA125. And CA153 were statistically analyzed by chemiluminescence. 3 data were analyzed by SPSS17.0 software. The data were normally distributed, expressed as mean 鹵standard deviation (x 鹵s), t test was used for comparison among groups, and x 2 test was used for comparison between qualitative data groups. The test level was 偽 0. 05. Results the serum SFCA125 and CA153 were in the breast cancer group. The expression level of serum SF was compared between benign breast disease group and healthy control group, and the difference was significant in breast cancer group and breast benign disease group (P 0.05). Serum CA125 and CA153 expression levels were significantly higher than those in breast benign disease group. The breast cancer group was significantly higher than the benign breast disease group and the healthy physical examination group, the difference was statistically significant (P 0.05). There was no significant difference in the expression of serum SF CA125 and CA153 in different stages of breast cancer. There was a significant difference in the level of serum SF expression between stage I and stage II of stage II, and there was a statistically significant difference in the level of expression of serum SF between stage 鈪，

本文編號(hào)：1552508